BACKGROUND Central venous catheters (CVC) are essential for the management of patients with hematologic malignancies, facilitating chemotherapy infusion, antibiotics, parenteral nutrition, blood products, and blood samples collection. In this population, peripherally inserted central catheters (PICC) seem to be associated with lower complications, compared with conventional percutaneously inserted devices (CICC). Data on the PICC in allogeneic hematopoietic stem cell recipients (allo-HSCT) are limited. METHODS We have prospectively evaluated the safety and efficacy of 100 polyurethanes or silicone PICC, inserted into 100 adult allo-HSCT recipients, at the Hematology of Sapienza University of Rome (Italy), between October 2012 and August 2017. RESULTS The median duration of PICC placement was 117 days. Overall, 68% of patients maintained the device for the entire transplant procedure and PICC were removed after day 100 from allo-HSCT; of these, 44% did not experienced any PICC-related complications. Catheter-related bloodstream infections (CRBSI) occurred in 32% of patients (2.5/1000 PICC days), associated with thrombosis in 8 cases. CRBSI were observed in 42% of patients with polyurethane and 20% with silicone PICC (p = 0.02). Catheter-related thrombosis occurred in 9% of patients, never requiring anticipated PICC removal. Mechanical complications occurred in 15% of cases (1.2/1000 PICC days). On the whole, adverse events were manageable and did not affect transplant outcome. No deaths related to PICC-complications were observed. CONCLUSIONS PICC are a safe and reliable long-term venous access in allo-HSCT recipients.

中文翻译：

---

异基因造血干细胞移植受者周围插入的中心导管。

背景技术中心静脉导管（CVC）对于血液系统恶性肿瘤患者的治疗，促进化学疗法输注，抗生素，肠胃外营养，血液制品和血液样本采集是必不可少的。与传统的经皮插入器械（CICC）相比，在这一人群中，外周插入中央导管（PICC）似乎具有较低的并发症。异基因造血干细胞受体（allo-HSCT）中PICC的数据有限。方法我们前瞻性评估了2012年10月至2017年8月在罗马的萨皮恩察大学（意大利）血液学中，将100种聚氨酯或有机硅PICC插入100名成人同种异体HSCT接受者中的安全性和有效性。结果安置是117天。总体，68％的患者在整个移植过程中都维护了该设备，并在第100天后从all-HSCT中移除了PICC；其中，有44％没有经历过与PICC相关的并发症。32％的患者（2.5 / 1000 PICC天）发生导管相关的血流感染（CRBSI），其中8例与血栓形成有关。在42％的聚氨酯患者和20％的硅氧烷PICC患者中观察到CRBSI（p = 0.02）。9％的患者发生了与导管相关的血栓形成，从不要求预期的PICC清除。机械并发症发生在15％的病例中（1.2 / 1000 PICC天）。总体而言，不良事件是可以控制的，并且不影响移植结果。没有观察到与PICC并发症相关的死亡。结论PICC是同种HSCT接受者长期安全可靠的静脉通路。